Abstract
Even though protein tyrosine phosphatase has been identified as a validated therapeutic target over a decade for type II diabetes and obesity, developing a selective inhibitor to protein tyrosine phosphatase 1B (PTP1B) over other cellular PTPases has been a complicated task owing to the highly conserved and polar nature of the PTP1B catalytic site. Virtual screening study of in-house chemical depository resulted in the prioritization of few low molecular weight compounds as PTP1B inhibitors. The in-vitro pNPP assays were carried out on prioritized compounds in both PTP1B and T-cell protein tyrosine phosphatase (TCPTP). From this we identified four low molecular weight compounds as PTP1B inhibitors, of which the compound AU-2439 has shown 5 fold selectivity towards PTP1B over highly homologous TCPTP. In this short communication selectivity of AU-2439 is explained based on interaction with critical active site residues in both proteins using docking models.
Keywords: PTP1B, TCPTP, p-Nitro phenyl phosphate, Type II diabetes, Obesity.
Mini-Reviews in Medicinal Chemistry
Title:Diphenylether Derivative as Selective Inhibitor of Protein Tyrosine Phosphatase 1B (PTP1B) Over T-cell Protein Tyrosine Phosphatase (TCPTP) Identified through Virtual Screening
Volume: 13 Issue: 11
Author(s): M. V.V.V. Sekhar Reddy, Chakshusmathi Ghadiyaram, Sunil Kumar Panigrahi, Subramanya Hosahalli and Lakshmi Narasu Mangamoori
Affiliation:
Keywords: PTP1B, TCPTP, p-Nitro phenyl phosphate, Type II diabetes, Obesity.
Abstract: Even though protein tyrosine phosphatase has been identified as a validated therapeutic target over a decade for type II diabetes and obesity, developing a selective inhibitor to protein tyrosine phosphatase 1B (PTP1B) over other cellular PTPases has been a complicated task owing to the highly conserved and polar nature of the PTP1B catalytic site. Virtual screening study of in-house chemical depository resulted in the prioritization of few low molecular weight compounds as PTP1B inhibitors. The in-vitro pNPP assays were carried out on prioritized compounds in both PTP1B and T-cell protein tyrosine phosphatase (TCPTP). From this we identified four low molecular weight compounds as PTP1B inhibitors, of which the compound AU-2439 has shown 5 fold selectivity towards PTP1B over highly homologous TCPTP. In this short communication selectivity of AU-2439 is explained based on interaction with critical active site residues in both proteins using docking models.
Export Options
About this article
Cite this article as:
Reddy V.V.V. Sekhar M., Ghadiyaram Chakshusmathi, Panigrahi Kumar Sunil, Hosahalli Subramanya and Mangamoori Narasu Lakshmi, Diphenylether Derivative as Selective Inhibitor of Protein Tyrosine Phosphatase 1B (PTP1B) Over T-cell Protein Tyrosine Phosphatase (TCPTP) Identified through Virtual Screening, Mini-Reviews in Medicinal Chemistry 2013; 13 (11) . https://dx.doi.org/10.2174/1389557511313110006
DOI https://dx.doi.org/10.2174/1389557511313110006 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Drugs and Mitochondria
Mitochondria play a central role in the life and death of cells. They are not merely the center for energy metabolism but are also the headquarters for different catabolic and anabolic processes, calcium fluxes, and various signaling pathways. Mitochondria maintain homeostasis in the cell by interacting with reactive oxygen-nitrogen species ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TRP Channels in the Digestive System
Current Pharmaceutical Biotechnology Adult and Embryonic Stem Cells in Cartilage Repair
Current Rheumatology Reviews Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis
Current Vascular Pharmacology Study of Time-dependent Interaction of ZnO Nanoparticles with Sucrose and Honey Molecules for Biomedical Applications
Current Nanomaterials Metallocarboxypeptidases and their Inhibitors: Recent Developments in Biomedically Relevant Protein and Organic Ligands
Current Medicinal Chemistry Editorial [Hot Topic: Recent Advances in Protein and Peptide Chemistry Related to Cellular Regulation (Guest Editor: John W. Ho)]
Protein & Peptide Letters Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney
Current Medicinal Chemistry Bone Changes in Patients with Inflammatory Arthritis Treated with Biological Therapies: A Clinical Perspective
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Extract of <i>Moringa concanensis</i> Nimmo Leaves Ameliorates Hyperglycemia and Oxidative Stress, and Improves β-cell Function in Alloxan Monohydrate Induced Diabetic Rats
Current Bioactive Compounds The Medicinal Chemistry of Peptides
Current Medicinal Chemistry COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: A Proposed Classification and Treatment Strategies
Infectious Disorders - Drug Targets Circulating Tumor Stem Cells as Biomarkers for Cancer Progression
Recent Patents on Biomarkers CADA, a Potential Anti-HIV Microbicide that Specifically Targets the Cellular CD4 Receptor
Current HIV Research Pathophysiology of Sepsis and Recent Patents on the Diagnosis, Treatment and Prophylaxis for Sepsis
Recent Patents on Inflammation & Allergy Drug Discovery Emerging Targets for the Treatment of Dyslipidemia
Current Medicinal Chemistry Imaging Subclinical Atherosclerosis: Where Do We Stand?
Current Cardiology Reviews Imaging Findings of Calcifying Nested Stromal-Epithelial Tumour of the Liver: A Case Report and Literature Review
Current Medical Imaging Gender Differences in Autonomic Control of the Cardiovascular System
Current Pharmaceutical Design MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design